Approximately 500,000 individuals in the United States require kidney replacement therapy for end-stage renal disease (ESRD), and over $40 billion are annually spent in hemodialysis (HD) and kidney transplant treatments for these patients. Despite improvements in the HD technology, the mortality rate of HD patients is still exceptionally high, with a 5-year survival rate of only 35%. Patients succumb to conditions that result from the chronic inflammation caused by contact of the blood with the HD filters. This blood-filter interaction can activate the complement system, which is a strong mediator of inflammatory processes. Although kidney transplantation provides improved quality of life and survival rates over dialysis, the organ shortage and compatibility issues limit the number of transplants performed worldwide. Also, the period of cold ischemia observed during organ collection induces the activation of complement and inflammation, contributing to graft rejection and loss in approximately 4% of the transplanted patients. Thus, inflammatory immune responses are involved in several aspects of HD- and transplantation-related complications. Notably, recent reports indicate promising effects of therapeutic inhibition of complement by modulating inflammatory responses during HD and transplantation. This proposal therefore presents a comprehensive study to investigate complement-mediated inflammatory mechanisms induced during HD and kidney transplantation and evaluates a panel of complement inhibitors for their ability to attenuate such inflammatory processes.
Aim 1 will use an established extracorporeal circulation model in combination with biochemical, proteomic, and cellular assays to dissect the complement pathways and effectors involved in the HD procedure and the inflammatory networks triggered. The evaluation of blood from ESRD patients and the establishment of an in vivo HD model in non-human primates will enhance the applicability of the results from this aim to clinical situations.
In Aim 2, similar biochemical and cellular assays will be used to dissect the complement pathways and effectors involved during kidney ischemia and reperfusion, and the clinical potential of the complement inhibitor compstatin to prevent organ rejection will be evaluated in an established non-human primate model of ABO-incompatible kidney transplantation. The results obtained are expected to: 1) provide a broad insight into the impact of individual complement pathways and associated effector networks on the detrimental processes that contribute to morbidity and mortality in HD and transplant patients, and 2) arrive at potent and cost-effective treatment options for chronic inflammatory conditions in HD and kidney transplant patients through the inhibition of complement.
The objectives of this proposal are to 1) dissect the mechanisms by which the complement system regulates and promotes inflammation during the treatment of kidney disease, and 2) use appropriate complement inhibitors as rational therapeutic interventions in animal models of hemodialysis, renal transplantation, and ischemia-reperfusion injury. This study will facilitate the development of innovative treatment modalities for
|Schmidt, Christoph Q; Harder, Markus J; Nichols, Eva-Maria et al. (2016) Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology 221:503-11|
|Blatt, Adam Z; Saggu, Gurpanna; Kulkarni, Koustubh V et al. (2016) Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. J Immunol 196:4671-80|
|Mastellos, Dimitrios C; Reis, Edimara S; Yancopoulou, Despina et al. (2016) From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology 221:1046-57|
|Hajishengallis, George; Lambris, John D (2016) More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation. Immunol Rev 274:233-244|
|Lindorfer, Margaret A; Cook, Erika M; Reis, Edimara S et al. (2016) Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clin Immunol 171:32-35|
|Maekawa, Tomoki; Briones, Ruel A; Resuello, Ranillo R G et al. (2016) Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J Clin Periodontol 43:238-49|
|Hajishengallis, George; Hajishengallis, Evlambia; Kajikawa, Tetsuhiro et al. (2016) Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin Immunol 28:285-91|
|Ricklin, Daniel; Reis, Edimara S; Lambris, John D (2016) Complement in disease: a defence system turning offensive. Nat Rev Nephrol 12:383-401|
|Hajishengallis, George; Moutsopoulos, Niki M (2016) Role of bacteria in leukocyte adhesion deficiency-associated periodontitis. Microb Pathog 94:21-6|
|Wang, Junxiang; Wang, Lu; Xiang, Ying et al. (2016) Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clin Immunol 162:37-44|
Showing the most recent 10 out of 186 publications